ARTICLE | Clinical News
ALX-0141: Phase I data
September 27, 2010 7:00 AM UTC
In an ongoing, double-blind, placebo-controlled Phase I trial in 42 healthy postmenopausal women, single subcutaneous injections of 0.003-1 mg/kg ALX-0141 were well tolerated with no serious adverse e...